Trading Analysis Report: TMO
- Analysis date: 2026-05-29
- Processed decision: Buy
- Price Target: $612
I. Analyst Team Reports
Market Analyst
Market Analyst
Investment Snapshot
| Metric | Latest value | Why it matters |
|---|---|---|
| NYSE close (May 29, 2026) | $492.51 | Entry price for the rating and target. |
| Market capitalization | $183.03B | Thermo Fisher remains a global life-science tools leader. |
| Enterprise value | $223.06B | Debt-adjusted value is meaningful after acquisitions. |
| 52-week range | $385.46-$643.99 | Shares are below the prior high and still in recovery mode. |
| 50-day / 200-day averages | $479.61 / $526.78 | Price is above the 50-day average but below the 200-day average. |
| Forward P/E | 18.04x | Valuation is reasonable for a high-quality science tools platform. |
| Trailing P/E | 27.11x | GAAP multiple is higher due to acquisition amortization and charges. |
| Price/sales | 4.05x | Revenue multiple is fair for a diversified life-science leader. |
| EV/revenue | 4.94x | Enterprise valuation reflects leverage and quality. |
| EV/EBITDA | 19.75x | EBITDA multiple is premium but not extreme versus quality. |
| Dividend yield | 0.38% | The investment case is capital appreciation, not income. |
| Analyst mean / median target | $611.56 / $615.00 | Consensus implies material upside from the close. |
| Analyst high / low target | $750.00 / $490.00 | Downside appears limited in consensus, but dispersion remains. |
| Q1 2026 revenue | $11.01B, +6% | Top-line growth improved from the 2025 base. |
| Q1 2026 organic revenue growth | +1% | Underlying demand is positive but still modest. |
| Q1 2026 GAAP diluted EPS | $4.43, +11% | Reported earnings improved year over year. |
| Q1 2026 adjusted EPS | $5.44, +6% | Adjusted earnings growth supports the Buy case. |
| Q1 2026 adjusted operating income | $2.40B | Profit scale remains strong. |
| Q1 2026 adjusted operating margin | 21.8% | Margin was nearly stable year over year. |
| Q1 2026 capital deployment | Clario, $3.0B buybacks, 10% dividend increase | Management is using capital actively. |
| FY2025 revenue / organic growth | $44.56B / +2% | 2025 showed a low-growth but resilient base. |
| FY2025 adjusted EPS | $22.87, +5% | Earnings growth continued despite modest organic growth. |
| FY2025 operating cash flow | $7.818B | Cash generation supports deleveraging and capital returns. |
TMO closed at $492.51 on May 29, 2026, below the 200-day average of $526.78 and well below the analyst mean target of $611.56. The stock has recovered from its low but still trades meaningfully below consensus fair value.
The operating setup supports a Buy. Q1 2026 revenue grew 6% to $11.01 billion, adjusted EPS grew 6% to $5.44, adjusted operating income was $2.40 billion, and adjusted operating margin was 21.8%. The company also completed the Clario acquisition, repurchased $3.0 billion of stock, and increased its dividend by 10%.
The main caveat is organic growth. Q1 organic revenue growth was only 1%, so this is not a high-growth call. A $612 target, close to the analyst mean target, reflects a recovery to fair value rather than an aggressive rerating.
Sentiment Analyst
Sentiment Analyst
Sentiment is improving. Thermo Fisher delivered a strong Q1 2026 headline result with 6% revenue growth, 11% GAAP EPS growth, and 6% adjusted EPS growth. Investors also saw clear capital deployment: Clario closed, $3.0 billion of stock was repurchased, and the dividend was raised 10%.
The customer narrative is also constructive. Management highlighted product launches across cryo-EM, mass spectrometry, industrial analysis, and cell therapy manufacturing, plus strategic collaborations with NVIDIA and SHL Medical. These items reinforce Thermo Fisher's role as a broad partner to pharma, biotech, diagnostics, and laboratory customers.
The sentiment risk is that organic growth is still only modest. Q1 organic revenue growth was 1%, and the market may wait for stronger pharma/biotech funding and instrument demand before giving the stock a full multiple recovery. Still, with the share price below consensus targets and below the 200-day average, sentiment is asymmetric enough for a Buy.
News Analyst
News Analyst
The key news item is Thermo Fisher Scientific's first quarter 2026 results, released on April 23, 2026. Revenue grew 6% year over year to $11.01 billion. Organic revenue growth was 1%. GAAP diluted EPS grew 11% to $4.43, and adjusted EPS grew 6% to $5.44.
Profitability remained strong. GAAP operating income was $1.86 billion and GAAP operating margin was 16.9%, compared with 16.6% a year earlier. Adjusted operating income was $2.40 billion, and adjusted operating margin was 21.8%, compared with 21.9% a year earlier.
Capital deployment was active. During Q1, Thermo Fisher completed the acquisition of Clario, repurchased $3.0 billion of stock, and increased its dividend by 10%. The latest full-year release showed 2025 revenue of $44.56 billion, adjusted EPS of $22.87, adjusted operating income of $10.11 billion, and operating cash flow of $7.818 billion.
Sources: Thermo Fisher Scientific Q1 2026 results release dated April 23, 2026; Thermo Fisher Scientific Q4 and full-year 2025 results release dated January 29, 2026; market snapshot retrieved May 31, 2026 for the May 29, 2026 NYSE close.
Fundamentals Analyst
Fundamentals Analyst
Thermo Fisher's fundamentals are high quality. Q1 2026 revenue grew 6% to $11.01 billion, adjusted operating income reached $2.40 billion, adjusted operating margin was 21.8%, and adjusted EPS grew 6% to $5.44. The company continues to produce durable margins even when organic growth is modest.
The 2025 base was resilient. Full-year 2025 revenue grew 4% to $44.56 billion, organic revenue grew 2%, adjusted EPS grew 5% to $22.87, adjusted operating income was $10.11 billion, and GAAP operating cash flow was $7.818 billion. This supports the view that Thermo Fisher can compound through weaker funding cycles.
The balance sheet needs monitoring. The yfinance snapshot shows total debt of about $43.16 billion and cash of about $3.26 billion. That debt load is manageable given scale and cash flow, but it raises the importance of Clario integration, margin discipline, and continued free cash flow.
Valuation supports the thesis. TMO trades at 18.04x forward earnings and 4.05x sales, while the stock is below the 200-day average and materially below analyst mean and median targets. The fundamentals support Buy with a disciplined $612 target.
II. Research Team Decision
Bull Researcher
Bull Case
The bull case is that Thermo Fisher is a quality compounder trading below fair value. The company grew Q1 2026 revenue 6%, adjusted EPS 6%, and held adjusted operating margin near 22%. Its product breadth, pharma services, diagnostics, analytical instruments, and lab products create a diversified revenue base.
Capital allocation is also a positive. The Clario acquisition expands endpoint data capabilities, while $3.0 billion of share repurchases and a 10% dividend increase show management confidence. Strong operating cash flow gives Thermo Fisher room to fund acquisitions and buybacks while managing debt.
If organic growth improves from the 1% Q1 level and pharma/biotech demand stabilizes, the stock can move toward the $612 target and potentially higher consensus targets.
Bear Researcher
Bear Case
The bear case is that organic growth remains too slow. Q1 2026 organic revenue growth was only 1%, and the broader life-science tools industry is still sensitive to customer capital budgets, biopharma funding, and government research spending. A weak funding cycle could hold back revenue acceleration.
Debt is another risk. Total debt is about $43.16 billion in the market snapshot, and Clario adds integration and execution demands. If cash flow slows or interest costs remain high, investors could assign a lower multiple.
The stock is not extremely cheap. EV/EBITDA is about 19.75x and trailing P/E is about 27.11x. If growth stays muted, the market may not reward a Buy thesis quickly.
Research Manager
Research Manager Decision
The research decision is Buy with a $612 price target. Thermo Fisher combines durable earnings, strong margins, broad end-market exposure, and disciplined capital deployment. The stock is below the 200-day average and materially below analyst mean and median targets.
The target is not aggressive. A $612 target is close to the analyst mean target of $611.56 and below the median target of $615.00. It assumes a recovery toward consensus fair value as Clario integration, buybacks, and modest organic growth support earnings.
Price Target: $612
Rating: Buy.
III. Trading Team Plan
Trader
Trader Plan
TMO can be accumulated below the $612 target. The current price of $492.51 offers a favorable spread to consensus targets, and the stock is still below the 200-day average. A staged entry is appropriate because organic growth is modest and the stock may remain sensitive to life-science funding data.
Risk controls should focus on organic revenue growth, adjusted operating margin, Clario integration, debt reduction, and free cash flow. If organic growth remains stuck near 1% and leverage does not improve, the target should be revisited.
Upside confirmation would come from stronger pharma/biotech demand, improving instrument orders, and management raising 2026 guidance after Clario contribution becomes clearer.
IV. Risk Management Team Decision
Aggressive Analyst
Aggressive Risk Analyst
The aggressive view supports buying. Thermo Fisher has a world-class platform, resilient margins, and a strong history of acquisition integration. Q1 2026 revenue growth of 6% and adjusted EPS growth of 6% show that earnings are moving in the right direction.
The stock trades at only 18.04x forward earnings and below the 200-day average. For a high-quality life-science tools leader with consensus targets above $600, that setup is attractive. Buybacks should also improve per-share value.
Conservative Analyst
Conservative Risk Analyst
The conservative view is to size the position carefully. Organic revenue growth was only 1% in Q1 2026, and debt is high in absolute terms. Thermo Fisher needs better underlying demand and successful Clario integration to justify a large rerating.
Valuation is reasonable but not distressed. EV/EBITDA is near 20x, and the dividend yield is only 0.38%. Investors relying on total return need earnings growth and multiple recovery, not income protection.
Conservative investors can buy gradually rather than all at once.
Neutral Analyst
Neutral Risk Analyst
The balanced view is Buy with discipline. Thermo Fisher's scale, margins, cash generation, and capital allocation support the rating, while the stock's discount to consensus targets provides upside.
The offset is that organic growth is not yet strong. A $612 target is appropriate because it reflects fair-value recovery, not a full growth-stock rerating. The key monitoring points are organic growth, Clario integration, free cash flow, and debt.
V. Portfolio Manager Decision
Portfolio Manager
Portfolio Manager Decision
Final decision: Buy.
Price Target: $612
TMO is suitable for investors seeking high-quality life-science tools exposure with a valuation recovery setup. Q1 2026 revenue grew 6% to $11.01 billion, adjusted EPS grew 6% to $5.44, adjusted operating income was $2.40 billion, and adjusted operating margin was 21.8%. Management also completed Clario, repurchased $3.0 billion of stock, and increased the dividend 10%.
The stock closed at $492.51, below the 200-day average and materially below analyst mean and median targets. The $612 target is close to the analyst mean target and reflects a recovery toward fair value.
The main risks are weak organic growth, high debt, integration execution, and slower pharma/biotech funding. These risks argue for staged accumulation, but the current risk-reward supports Buy.